Skipnavigation

Activartis Logo


Seitenkopf

search

search in Activartis website

Metanavigation / Sprache


Slideshow

  • Slideshow Bild - Topmeldung
    design element

    Start

    Activartis’ proprietary technology platform is a completely individualised cancer immune therapy based on dendritic cells.  

  • For the manufacturing of Activartis’ tailored cancer vaccine, a patient’s tumour tissue as well as peripheral blood monocytes are collected.
    design element

    Step 1

    For the manufacturing of Activartis’ tailored cancer vaccine, a patient’s tumour tissue as well as peripheral blood monocytes are collected.  

  • Tumour antigens are extracted from the tumour cells; the monocytes are differentiated into dendritic cells.
    design element

    Step 2

    Tumour antigens are extracted from the tumour cells; the monocytes are differentiated into dendritic cells.  

  • The dendritic cells are charged with the tumour antigens and exposed to lipopolysaccharide and interferon-gamma. This is Activartis’ core process and comprises our intellectual property.
    design element

    Step 3

    The dendritic cells are charged with the tumour antigens and exposed to lipopolysaccharide and interferon-gamma. This is Activartis’ core process and comprises our intellectual property.  

  • Slideshow Bild - Topmeldung
    design element

    Step 4

    The dendritic cells are inoculated into one of the patient’s inguinal lymph nodes, where they present the tumour antigens to killer T-cells in order to trigger an anti-tumour immune response.  


Navigation

Servicemenü / Seite drucken



Activartis Biotech GmbH

Activartis is a biotech company based in Vienna and is developing a novel cancer immunotherapy concept in phase II clinical trial. Currently directed against aggressive brain cancer, it will in principle be applicable against all types of cancerous diseases.

The therapeutic platform combines a completely novel, proprietary approach by utilising a bacterial danger signal in combination with the patient’s tumour antigens together with the proven successful concept of dendritic cells to mobilise the patients’ immune system to combat the disease.

Thomas Felzmann, CEO Activartis


Fußbereich

Zusatznavigation

Inhaltsübersicht